论文部分内容阅读
目的:分析替吉奥联合奥沙利铂新辅助化疗治疗胃癌的疗效和安全性。方法:抽取2018年3月至2020年12月安阳市第六人民医院收治的胃癌患者88例，按照随机数字表法分为替吉奥组和奥沙利铂组，每组44例。奥沙利铂组予以奥沙利铂新辅助化疗治疗，替吉奥组予以替吉奥与奥沙利铂新辅助化疗联合治疗。比较两组疗效、肿瘤标志物、免疫功能、功能状态评分量表(KPS)评分、不良反应、生存率。结果:替吉奥组总有效率(84.09%，37/44)高于奥沙利铂组(61.36%，27/44)，n P<0.05。治疗后，替吉奥组糖类抗原199、糖类抗原242低于奥沙利铂组(n P<0.05)。替吉奥组CD3n +、CD4n +高于奥沙利铂组(n P<0.05)，替吉奥组KPS评分高于奥沙利铂组(n P0.05)。替吉奥组2年生存率(81.82%，36/44)高于奥沙利铂组(54.55%，24/44)，n P<0.05。n 结论:替吉奥与奥沙利铂新辅助化疗联合治疗胃癌患者效果确切，可改善免疫功能，调节肿瘤标志物表达，治疗安全性良好，可改善机体状况和生活质量，延长生存期，提高远期预后效果。“,”Objective:To analyze the efficacy and safety of neoadjuvant chemotherapy with tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of gastric cancer.Methods:Eighty-eight patients with gastric cancer treated in Anyang Sixth People’s Hospital from March 2018 to December 2020 were selected and divided into tegafur, gimeracil and oteracil porassium group (S1 group) and oxaliplatin group according to random number table method, with 44 patients in each group. The oxaliplatin group was treated with oxaliplatin neoadjuvant chemotherapy, and the S1 group was treated with neoadjuvant chemotherapy combined with tegafur, gimeracil and oteracil porassium capsules and oxaliplatin. Efficacy, tumor markers, immune function, Karnofsky performance status scale (KPS) score, adverse reactions and survival rate were compared between the two groups.Results:The total effective rate in S1 group was 84.09%(37/44), which was higher than the 61.36%(27/44) in oxaliplatin group (n P<0.05). After treatment, carbohydrate antigen 199 and carbohydrate antigen 242 in S1 group were lower than those in oxaliplatin group (n P<0.05). After treatment, the levels of cluster of differentiation3 (CD3)n + and cluster of differentiation 4 (CD4)n + in S1 group were higher than those in oxaliplatin group (n P<0.05). After treatment, KPS score in S1 group was higher than that in oxaliplatin group (n P0.05. The 2-year survival rate of S1 group was 81.82% (36/44), which was higher than that of oxaliplatin group (54.55%, 24/44),n P<0.05.n Conclusions:Tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin neoadjuvant chemotherapy is effective in the treatment of patients with gastric cancer. It can improve immune function, regulate the expression of tumor markers, with good treatment safety. It can improve the body condition and quality of life, prolong survival, and improve long-term prognostic effect.